← back to search

Wei Yang

Zhejiang International Studies University · CN
Area of research
Electrical and Electronic Engineering · Control and Systems Engineering
Research interest
Research interests include Robot Manipulation and Learning, Perovskite Materials and Applications, Chronic Myeloid Leukemia Treatments, and Advancements in Battery Materials.
h-index
25
citations
2,307
works
278
NIH funding
primary concept
email

Recent publications

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Experimental Hematology and Oncology 2025cited by 2position: middledoi
3D-Printed Microneedles with Controlled Structures for Drug Delivery Study in an Ex Vivo Model
Micromachines 2025cited by 1position: middledoi
YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity
Nature Communications 2024cited by 23position: middledoi
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment
Frontiers in Immunology 2024cited by 21position: middledoi
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
Blood 2024cited by 9position: middledoi
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
Cancer Pathogenesis and Therapy 2024cited by 3position: middledoi
DOCTer: a novel EEG-based diagnosis framework for disorders of consciousness
Journal of Neural Engineering 2024cited by 2position: middledoi
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)
Blood 2023cited by 9position: firstdoi
Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia
Blood 2023cited by 5position: middledoi
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)
Blood 2023cited by 5position: middledoi
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Blood 2023cited by 2position: middledoi
Validation of the imatinib-therapy failure model
Leukemia 2023cited by 2position: middledoi
Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
American Journal of Hematology 2023cited by 0position: middledoi
Pulmonary Dysfunction in Patients Recovered from COVID-19 Pneumonia: A 6-Month Follow-up Study
2020cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2023–2023)Hong Liu · Fudan University1 papers (2025–2025)Yan Liu · Sichuan Academy of Agricultural Sciences1 papers (2020–2020)Zhenling Li · Jilin University1 papers (2023–2023)Daijing Yuan · NewGen Therapeutics (United States)1 papers (2025–2025)Xingxing Meng · Guangxi Medical University1 papers (2025–2025)Lin Yang · Hebei Medical University1 papers (2023–2023)Ying Xie · Shanxi Medical University1 papers (2023–2023) · 1 papers (2025–2025)Nishanthan Rajakumaraswamy · Gilead Sciences (United States)1 papers (2025–2025) · 1 papers (2024–2024)Zhenjiu Wang · Ludwig-Maximilians-Universität München1 papers (2023–2023) · 1 papers (2025–2025)Shishuai Meng · Harbin Medical University1 papers (2020–2020)Songlin Yang · Harbin Medical University1 papers (2020–2020)Bing Xu · Nanjing University of Chinese Medicine1 papers (2023–2023)Dongsheng Fei · Harbin Medical University1 papers (2020–2020)Yanxia Shi · University of Colorado Denver1 papers (2024–2024)Sanfang Tu · Zhujiang Hospital1 papers (2023–2023) · 1 papers (2023–2023)